ANIK - Anika Therapeutics, Inc.

QQQ $ 472.49 $ -2.05 (-0.43 %)

DIA $ 416.26 $ -1.07 (-0.26 %)

SPY $ 562.20 $ -1.67 (-0.3 %)

TLT $ 99.62 $ -1.25 (-1.24 %)

GLD $ 235.53 $ -1.83 (-0.77 %)

Previous Close

$ 25.47

Open

$ 24.99

Bid

$ 25.36 x 103

Ask

-- x --

Day's Range

$ 24.95 - $ 25.99

52 Week Range

$ 16.81 - $ 29.12

Volume

43,594

Average Volume

Market Cap

376.87M

Beta (5Y Monthly)

$ 1.02

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	03-15-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	03-16-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	03-11-2022	12-31-2021	10-K
12	11-04-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-07-2021	03-31-2021	10-Q
15	03-05-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-07-2020	06-30-2020	10-Q
18	05-22-2020	03-31-2020	10-Q
19	03-06-2020	12-31-2019	10-K
20	10-28-2019	09-30-2019	10-Q
21	07-26-2019	06-30-2019	10-Q
22	05-06-2019	03-31-2019	10-Q
23	02-27-2019	12-31-2018	10-K
24	10-26-2018	09-30-2018	10-Q
25	07-31-2018	06-30-2018	10-Q
26	05-10-2018	03-31-2018	10-Q
27	02-27-2018	12-31-2017	10-K
28	10-27-2017	09-30-2017	10-Q
29	07-28-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	02-24-2017	12-31-2016	10-K
32	11-01-2016	09-30-2016	10-Q
33	08-01-2016	06-30-2016	10-Q
34	05-03-2016	03-31-2016	10-Q
35	03-10-2016	12-31-2015	10-K
36	11-03-2015	09-30-2015	10-Q
37	08-04-2015	06-30-2015	10-Q
38	05-04-2015	03-31-2015	10-Q
39	03-13-2015	12-31-2014	10-K
40	11-06-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Barrington Research Maintains Outperform o...
08/09/2024 21:44:52

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $37 p...

Anika Therapeutics Affirms FY2024 Sales Gu...
08/08/2024 21:04:03

Fiscal 2024 Guidance Anika continues to expect that revenue for fiscal 2024 will be in the range of $168 to $173 million, repr...

Anika Therapeutics Q2 2024 Adj. EPS $0.17 ...
08/08/2024 21:01:53

Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0...

Anika Therapeutics Announces Full Market R...
07/11/2024 12:36:04

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's pro...

Peeling Back The Layers: Exploring Anika T...
05/29/2024 16:00:37

Stephens & Co. Reiterates Equal-Weight on ...
05/29/2024 13:21:25

Stephens & Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:ANIK) with a Equal-Weight and maintains $24 ...

Anika Authorizes $40M Share Repurchase Pro...
05/28/2024 20:09:56

Anika Enters Into Cooperation Agreement Wi...
05/28/2024 20:09:36

Barrington Research Maintains Outperform o...
05/09/2024 16:17:36

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $37 p...

Anika Says Cost Reduction Initiatives Comp...
05/08/2024 22:31:43

The Company expects adjusted EBITDA for 2024 to be $25 to $30 million, up over 75% at the midpoint, representing an adjusted EB...

Anika Announces Steve Griffin Appointed To...
05/08/2024 21:56:27

Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced ...

Anika Therapeutics Q1 2024 Adj EPS $0.09 B...
05/08/2024 20:11:08

Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(...

Barrington Research Maintains Outperform o...
03/14/2024 14:15:33

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the pric...

Stephens & Co. Reiterates Equal-Weight on ...
03/14/2024 13:55:13

Stephens & Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:ANIK) with a Equal-Weight and maintains $22 ...

Anika Therapeutics: Q4 Earnings Insights
03/13/2024 20:40:17

Anika Therapeutics Q4 2023 Adj EPS $0.05 B...
03/13/2024 20:36:18

Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(...

Anika Therapeutics Sees FY24 Revenue $168M...
03/13/2024 20:35:45

Fiscal 2024 GuidanceIn 2024, Anika is prioritizing accelerated growth in profitability, with a focus on the products with the g...

Earnings Scheduled For March 13, 2024
03/13/2024 10:15:56

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

Earnings Outlook For Anika Therapeutics
03/12/2024 15:00:45

Barrington Research Maintains Outperform o...
01/03/2024 15:12:16

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the pric...